From the Research
To manage psoriasis, a combination approach using topical corticosteroids and non-steroid containing products is recommended, with clobetasol propionate spray 0.05% being a highly effective option, as shown in a study published in 2022 1. The management of psoriasis involves a multi-faceted approach, considering the severity of the disease, patient preferences, and potential side effects of treatments.
- Topical corticosteroids, such as clobetasol propionate, are the cornerstone of psoriasis therapy, especially for mild to moderate cases, due to their anti-inflammatory, immunosuppressive, and antimitotic effects 2.
- A study from 2011 demonstrated the efficacy and safety of a weekday/weekend treatment regimen involving calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% for moderate plaque psoriasis 3.
- More recent research from 2022 compared the efficacy of topical cyclosporine cream assisted by fractional carbon dioxide laser versus topical clobetasol cream for the treatment of plaque psoriasis, showing that laser-assisted delivery of topical cyclosporine can provide comparable clinical and pathological improvement to that of clobetasol in psoriatic plaques 1.
- However, the 2022 study also found that topical clobetasol cream showed more improvement than the cyclosporine cream, highlighting the effectiveness of clobetasol propionate in managing psoriasis 1.
- Another study from 2020 discussed the use of a new clobetasol propionate 0.025% cream formulation that maintains super-potency without the need for traditional potency enhancement, offering a potentially safer alternative for long-term use 4.
- The choice of treatment should consider factors such as disease severity, patient compliance, and potential side effects, with regular follow-up being crucial to adjust the treatment regimen as needed.
- Given the most recent and highest quality evidence, clobetasol propionate spray 0.05% is recommended as a first-line treatment for managing psoriasis, due to its efficacy and safety profile, as demonstrated in the 2022 study 1.